IMPORTANCE Understanding how pneumococcal proteins affect the pathology of the middle ear and inner ear is important for the development of new approaches to prevent otitis media and its complications. SETTING AND PARTICIPANTS Twenty-seven chinchillas in an academic research laboratory.
O titis media is the most common indication for the prescription of antibiotics in the United States, 1 and pneumococci are responsible for 30% to 50% of otitis media cases in patients. 2 Bacterial resistance to antibiotics has necessitated the search for alternative methods for the prevention and treatment of acute otitis media. Although pneumococcal capsular polysaccharide vaccines are available, the current pneumococcal vaccine for children elicits antibody against a limited number of common serotypes. Furthermore, serotype replacement has become a serious problem. In otitis media vaccine trials, the vaccine groups had 33% more episodes of otitis media caused by serotypes not included in the vaccine. 3 Newer vaccine approaches have been developed that are based on the use of conserved external surface proteins, such as pneumococcal surface protein A (PspA) and PspC. Pneumococcal proteins, alone or in combination, are being investigated as potential vaccine candidates. 4 Pneumococcal surface protein A is a surface-bound protein that can bind to apolactoferrin to prevent its killing. 5 It has been shown to interfere with complement deposition on pneumococci, reducing opsonization and clearance of bacteria by the host immune system. 6 Pneumolysin (Ply) is a pore-forming protein that is cytotoxic and cytolytic. 7 Pneumolysin can activate the classic complement pathway 8 and prevent complement deposition on Streptococcus pneumoniae. 9 Other activities of Ply include promotion of inflammation, impairment of leukocyte function, inhibition of epithelial ciliary movement, and disruption of respiratory epithelial tight junctions. 10 Both PspA and Ply are expressed in most pneumococcal serotypes, making them good vaccine candidates.
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It was previously demonstrated that the pneumococcal mutant deficient in PspA was less virulent in the middle ear than a mutant deficient in Ply. 12, 13 In this study, we compared the viability and virulence of the Ply-deficient (Ply   −   ) and PspAdeficient (PspA − ) single mutants, the Ply − /PspA − double mutant, and their wild-type (Wt) parent strain D39 (serotype 2) in the middle ear and inner ear following inoculation in the chinchilla middle ear, as well as in vivo bacterial growth to assess host immunity on these strains.
Methods
The Institutional Animal Care and Use Committee of the University of Minnesota approved the care and use of the animals in these experiments. Streptococcus pneumoniae serotype 2 strain D39 (National Collection of Type Cultures 7466) 14 was the Wt used in our experiments and the parent strain for our mutants. This strain and its isogenic Ply − , PspA − , and Ply − / PspA − mutants have been described previously. [14] [15] [16] [17] Bacteria were grown in Todd-Hewitt broth (BD Diagnostics) containing 0.5% added yeast extract (BD Diagnostics) (hereinafter THB) plated on sheep blood agar plates and stored in 10% glycerin solution at −80°C. Mutants were grown on sheep blood agar plates and in THB, both containing 0.3 μg/mL of erythromycin. Bacteria were grown until they were in log phase. Their optical densities were measured at 660 nm on a spectrophotometer, and they were diluted to the desired concentration in phosphate-buffered saline. Ten-fold dilutions were plated, and viable cells were counted to confirm the actual concentration. The time-dependent viability of the PspA − mutant was also studied in THB at room temperature at 0 to 43 hours after inoculation. Strains were confirmed as S pneumoniae by optochin sensitivity and production of serotype 2 capsule using specific antisera as described previously. 18 The presence of Ply and PspA in all strains was analyzed from lysate preparations by Western blot using specific antisera as previously described. 19 All animals were anesthetized before bacterial inoculation with 0.25 mL of a combination of ketamine hydrochloride (100 mg/kg) and acepromazine maleate (10 mg/kg). Chinchilla middle ears were inoculated with 0. We knew that this method and inoculum would result in sufficient volumes of middle ear effusions (MEEs) and noticeable histopathological changes in most ears in the Wt strain and the protein-deficient mutants. Bullae were removed, and MEEs were harvested for bacterial counts. Cochleae from all groups were embedded in epoxy resin, sectioned at a thickness of 1 μm, and stained with toluidine blue. The round window membranes (RWMs) were bisected, and one side was randomly selected for histopathological evaluation. Images of the RWMs were obtained at ×1000 magnification at the center of the sample and at 1 mm to the right and left of the center. Images of the scala tympani (ST) were obtained immediately under adjacent areas of the RWMs. Analyses of the RWMs included RWM thickness and the number of inflammatory cells. Evaluation of the adjacent ST included inflammatory cell infiltration and measurement of the number of bacteria, the number of bacteria within inflammatory cells, and the number of bacteria free in the perilymph (per area). The measurements of these 3 selected areas of RWMs and the ST from each animal were averaged. The means of these numbers for Wt and mutant groups were then used for statistical analysis to compare all animal groups infected with the Wt or its isogenic mutant strains. All results are expressed as the mean (SE). Differences between the groups were analyzed with 1-way analysis of variance using statistical software (SPSS, version 18; SPSS Inc). Differences were considered significant at P ≤ .05.
The analysis of viability in the chinchilla middle ear included 30 animals inoculated bilaterally with 0.5 mL of 2.7 × 10 6 CFUs/mL of PspA − . Animals were killed at 6, 12, 18, 24, 30, and 36 hours after inoculation for bacterial counts of MEEs and histopathological analysis.
Results
At 48 hours after inoculation, CFU counts in MEEs ( Figure 1A at 48 hours after inoculation ( Figure 2F ). There was variability between animals in each infected group. Figure 3 shows the most severe pathologic RWMs and adjacent areas in each group. This RWM from a chinchilla inoculated with the Wt strain ( Figure 3A ) was thickened from inflammatory cell infiltration. Bacteria were observed in the ST, both free floating and within inflammatory cells. After inoculation with the Ply − mutant, the histopathological findings of the RWMs ( Figure 3B ) were similar to those of the Wt strain, with infiltration of inflammatory cells and bacteria in the RWMs and the ST. This RWM from the animal inoculated with the PspA − mutant ( Figure 3C ) was not as thick as in the other groups, and there was no penetration of bacteria into the ST.
No pathologic attenuation was observed in the Ply − /PspA − strain compared with that in the Wt or single-mutant strains ( Figure 3D ).
Discussion
Streptococcus pneumoniae continues to be one of the most commonly cultured organisms from middle ears of children with otitis media. Because of the increased antibiotic resistance of pneumococci, interest has focused on a vaccine to prevent pneumococcal otitis media. The current polysaccharidebased vaccines are successful in some populations against invasive pneumococcal diseases (bacteremia and meningitis); however, the vaccines are serotype specific and have poor re- sponse in children for protection against otitis media, especially in those younger than 2 years. 20 Furthermore, Eskola et al 3 found a reduction in the rate of otitis media due to the serotypes in the vaccine and those that cross-react with them, but an increase of 33% in the rate of acute otitis media was attributed to other pneumococcal serotypes. This suggests the need for a different vaccine approach. There is an interest in producing a vaccine based on 1 or more of the pneumococcal proteins. 21 This requires a thorough understanding of the effect of these proteins on the viability and virulence of pneumococci within the middle ear and inner ear to select the most suitable vaccine candidates. Two potential candidates are Ply and PspA. Both proteins are expressed in virtually all pneumococcal serotypes, and immunization with these antigens can provide serotype-independent protection against pneumococci. Both single mutants in our study, Ply − and PspA − , were less virulent (ie, they induced fewer histopathological changes to the RWMs compared with the Wt and double-mutant strains). The PspA − strain was the least virulent. At least in part, the de- reported similar results that colonization of the nasopharynx decreased 30-fold from day 1 to day 4 in mice inoculated with the PspA − mutant. In our study, the Wt and other mutant strains were still viable at 48 hours after middle ear inoculation, although CFU counts of the PspA − mutant decreased over time,
with low counts at 30 hours and no detectable levels at 48 hours. However, the in vitro experiment with the PspA − mutant in THB showed an expected increase of about 2 logs at 43 hours, suggesting that the PspA − mutant may be more susceptible to host factors in the ear. This is presumably because of killing of bacteria by apolactoferrin 5 or sensitivity to complement deposition. 22 In investigations of cobra venom-treated chinchillas, Sabharwal et al 23 found that strains limiting complement C 3 protein deposition on their surfaces more readily cause experimental otitis media. An intriguing finding in our study is that the viability and virulence of the Ply − /PspA − double mutant were not attenu- expression by S pneumoniae proteins. One pattern was characteristic of pneumococci in the brain and lungs and the other of pneumococci in the bloodstream. Based on the above findings, the expression of pneumococcal proteins seems to be organ specific.
A limitation of our study is that we used a pneumococcal strain that is rarely the cause of otitis media, and genetic background and variation can influence protection by anti-PspA antibodies. 27, 28 PspA proteins have been classified into 3 families and 6 clades. Ninety-eight percent of the PspAs are in family 1 (clades 1 and 2) and family 2 (clades 3-5). 29 Although antibodies against PspA can be cross-protective, in some cases this may be limited to the same family or the same clade. In a study of the distribution of PspA families in MEEs from children, Melin et al 30 found that most were distributed equally between families 1 and 2. Their findings suggest that a good vaccine candidate should include the 2 main PspA families. The PspA used in our study (serotype 2 strain D39) is from family 1 clade 2, should be protective against this family and clade, and may be cross-protective against other families and clades as well. It was outside the scope of this study to determine the mechanism for the lack of attenuation of the Ply − /PspA − double mutant in the ear (ie, whether it could be related to complement pathogen-associated molecular pattern recognition, a more active role of other pneumococcal virulence factors in the absence of Ply and PspA, or some other factor). However, it seems that pneumococcal proteins have diverse organspecific effects on the viability and virulence of pneumococci. Further study is needed to better understand the potential of these proteins and their combinations as vaccine candidates against different diseases in diverse anatomic locations caused by pneumococci.
